Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 30, Number 4—April 2024

CME ACTIVITY - Synopsis

Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021–2022

Timothy J. DoyleComments to Author , Megan Gumke, Danielle Stanek, Joshua Moore, Brian Buck, Timothy Locksmith, Kelly Tomson, Sarah Schmedes, George Churchwell, Shan Justin Hubsmith, Baskar Krishnamoorthy, Karalee Poschman, Brandi Danforth, Daniel Chacreton, and the outbreak investigation team1
Author affiliations: Florida Department of Health, Tallahassee, Florida, USA (T.J. Doyle, M. Gumke, D. Stanek, J. Moore, B. Buck, T. Locksmith, K. Thomson, S. Schmedes, G. Churchwell, S.J. Hubsmith, B. Krishnamoorthy, K. Poschman, B. Danforth, D. Chacreton); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T.J. Doyle, K. Poschman)

Main Article

Figure 4

Persons vaccinated by month and antigen during concurrent outbreaks of hepatitis A, invasive meningococcal disease, and mpox, Florida, USA, 2021–2022. The figure shows the number of adult persons (>18 years of age) vaccinated with their first dose, by month the first dose was administered. For hepatitis A, the number includes persons vaccinated with any Food and Drug Administration (FDA)–approved vaccine against hepatitis A virus. For meningococcal disease, the number includes persons vaccinated with any FDA-approved serogroup ACWY vaccine (Menveo [GlaxoSmithKline], Menactra [Sanofi Pasteur, Inc.], MenQuadfi [Sanofi Pasteur, Inc.]). For mpox, the number includes persons vaccinated with JYNNEOS (Bavarian Nordic). FDA, Food and Drug Administration.

Figure 4. Persons vaccinated by month and antigen during concurrent outbreaks of hepatitis A, invasive meningococcal disease, and mpox, Florida, USA, 2021–2022. The figure shows the number of adult persons (>18 years of age) vaccinated with their first dose, by month the first dose was administered. For hepatitis A, the number includes persons vaccinated with any Food and Drug Administration (FDA)–approved vaccine against hepatitis A virus. For meningococcal disease, the number includes persons vaccinated with any FDA-approved serogroup ACWY vaccine (Menveo [GlaxoSmithKline], Menactra [Sanofi Pasteur, Inc.], MenQuadfi [Sanofi Pasteur, Inc.]). For mpox, the number includes persons vaccinated with JYNNEOS (Bavarian Nordic). FDA, Food and Drug Administration.

Main Article

1Members of the team are listed at the end of the article.

Page created: February 06, 2024
Page updated: March 18, 2024
Page reviewed: March 18, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external